Stomach Cancer Exosome-based Detection

Last updated: July 3, 2024
Sponsor: City of Hope Medical Center
Overall Status: Completed

Phase

N/A

Condition

Neoplasms

Digestive System Neoplasms

Genitourinary Cancer

Treatment

DESTINEX

Clinical Study ID

NCT06342427
23228/DESTINEX
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histological diagnosis of stage I, II, III, IV gastric cancer (TNM classification, 8th edition) (cases).

  • Received standard diagnostic and staging procedures as per local guidelines, and atleast one sample was drawn before receiving any curative-intent treatment.

  • Confirmed cancer-free status at the time of study inclusion (Non-disease controls).

Exclusion

Exclusion Criteria:

  • Lack of written informed consent.

  • Systemic therapy before sampling.

  • Synchronous gastric and non-gastric cancer diagnosed at or before surgery.

Study Design

Total Participants: 809
Treatment Group(s): 1
Primary Treatment: DESTINEX
Phase:
Study Start date:
March 15, 2023
Estimated Completion Date:
June 15, 2024

Study Description

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. Because conventional endoscopy is invasive and costly, gastric cancer is currently not considered to be screenable at a population level. However, if one could find less invasive and cheaper tools that accurately detect gastric cancer in its early stages, it could make a significant difference. Accurate biomarkers could help identify patients with gastric cancer before it becomes incurable.

This study aims to develop a non-invasive test to detect gastric cancer early. It consists of four phases:

  1. Discovering potential biomarkers with a comprehensive and genome-wide transcriptomic sequencing analysis that will involve gastric cancer tissue, normal tissue, and serum samples from patients with gastric cancer, as well as samples from people without the disease.

  2. Using machine learning to develop a combination "signature" of cell-free (cf) and exosomal (exo)-miRNA in serum specimens from a training cohort.

  3. A validation of this signature in an independent cohort to confirm its accuracy.

  4. An evaluation of the temporal trend of this signature in paired samples collected pre-surgery and post-surgery to investigate their potential and specificity as indicators of minimal residual disease.

In summary, this study aims to develop a highly accurate and cost-effective blood test for detecting gastric cancer early. Success could lead to significant improvements in clinical practice by catching cancer when it is most treatable. By combining different genetic markers (cell-free microRNA and exosomal microRNA) for accuracy, this study has the potential to reduce gastric cancer deaths and could lead to new screening methods in the future.

Connect with a study center

  • Nagoya University

    Nagoya,
    Japan

    Site Not Available

  • Mie University

    Tsu,
    Japan

    Site Not Available

  • City of Hope Medical Center

    Duarte, California 91010
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.